Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

The study will enroll participants in whom treatment with ceftobiprole has been completed (including both on-label and off-label use) plus at least one of the following criteria (more than one criterion may apply): * Participants with severe renal impairment / ESRD (end-stage renal disease, defined as calculated CLCr ( creatinine clearance) \< 30 mL/minute or oliguria \< 20 mL/hour unresponsive to fluid challenge or any form of dialysis) * Impaired baseline hepatic function (patients with liver failure/cirrhosis Child Pugh Grade A, B, C or existing non-cirrhotic liver disease associated with total bilirubin \> 2 mg/dL or alanine aminotransferase \[ALT\], or aspartate aminotransferase \[AST\] ≥ 3 times upper limit of the normal range \[ULN\]) * Participants with immunosuppression, i.e., * HIV-positive with CD4 (cluster of differentiation 4) counts of ≤ 0.2 × 10E9/L (≤ 200 cells/mm3) * Immunocompromised as determined by the investigator (any type or aetiology) * Baseline neutropenia or baseline myelosuppression, defined as presence of myelosuppression or neutropenia (absolute neutrophil count \[ANC\] ≤ 0.5 × 10E9/L \[\< 500 polymorphonuclear neutrophils (PMNs)/mm3\]), severe anaemia (haemoglobin \< 6.5 g/dL), or severe thrombocytopenia (\< 49.9 × 10E9/mm3) In addition, the study will enroll a control group of patients in whom treatment has been completed without any of the criteria listed above.